国药控股主业遇冷,医药流通龙头的增长神话还能延续吗?

华夏时报网
Nov 14

作为国内医药流通行业的龙头企业,国药控股(股票代码:1099.HK)近期的业绩表现引发了市场的广泛关注。尽管其营收规模在行业内持续保持领先地位,但陷入净利润增长显著放缓的困境。  业绩承压的背后,是公司三大核心业务板块集体面临增长挑战。作为营收“压舱石”的医药分销业务增长乏力,医疗器械板块同样未能摆脱增长瓶颈,就连曾被寄予厚望的医药零售业务,其增长也伴随着战略调整的阵痛。政策环境的变化成为影响业务...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10